MoonLake Immunotherapeutics remains a promising clinical-stage biotech, with potentially its first FDA approval in 2026.

Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 ...

Authorities in Wyoming say the search for Grant Gardner continue and have ramped up as the Lakeville native has not been ...

MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the 10 Stocks with Huge Catalysts on the Horizon. The company speeds up the clinical momentum with phase 3 trials, expanded indications, and ...

MoonLake stock has seen a 400% increase in value since its listing on the Nasdaq, and has raised over $450 million through equity offerings. Read more here.

MoonLake has recently announced the successful outcome of its end-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) the E.U. European Medicines Agency (EMA), with both ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where MoonLake Immunotherapeutics (NASDAQ:MLTX) stands ...

MoonLake will be hosting an R&D Day for investors and analysts in San Diego, USA on Sunday, March 10 alongside the American Academy of Dermatology (AAD) annual meeting.

MoonLake also announced a Capital Markets Day to be held in New York at NASDAQ, including a virtual webcast format, on September 11 th 2023. This session will be used to discuss the PsA market and ...

F or two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most ...

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10. A successful year including the announcements of positive ...